Latest Breaking News On - பிராங்க்ஃபர்ட் பெர்சே - Page 3 : comparemela.com
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T [ ]
cataniaoggi.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cataniaoggi.it Daily Mail and Mail on Sunday newspapers.
CSE: BIOV, FRA:5LB,OTCQB:BVAXF)
( BioVaxys or the
Company ) is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the
Private Placement ).
Final Tranche ) of the Private Placement, the Company issued 5,349,455 units (
Units ) at a price of $0.22 per Unit for total gross proceeds of approximately $1,176,880. Including the first tranche of the Private Placement which completed on July 14, 2021, the Company raised total aggregate gross proceeds of $2,015,555. Each Unit is comprised of one common share in the capital of the Company (a
Common Share ) and one whole Common Share purchase warrant (a
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
CSE: BIOV, FRA:5LB,OTCQB: BVAXF)
( BioVaxys or the Company ) is pleased to announce that it has closed the first tranche ( Tranche 1 ) of its previously announced non-brokered private placement (the Private Placement ). Pursuant to Tranche 1 of the Private Placement, the Company has issued 3,812,159 units ( Units ) at a price of $0.22 per Unit for gross proceeds of $838,675. Each Unit consists of one common share (a Common Share ) and one whole Common Share purchase warrant (a Warrant ). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.50 for a period of 30 months.
The aggregate Private Placement consists of the sale of up to 9,090,909 Units for total gross proceeds of up to approximately $2,000,000. Closing of the second tranche of the Private Placement is anticipated to complete within the next week.